Figure 2.

EphA2 signaling pathways in MMC. A. EphA2 signaling promotes oncogenic phenotype. In the absence of ligand, receptor EphA2 kinase function increases by RAS, AKT and MAPK activation which promotes malignancy. B. EphrinA1 binding of EphA2 induces tumor suppressive signals. Activation of EphA2 with EphrinA1 leads to phos-phorylation of EphA2 and inhibits RAS/MAPK pathways. EphrinA1 activation of MMC induced miR-Let-7a which targets RAS signaling and inhibits oncogenic signals in MMC. Phosphorylation = P; inhibition = -L; activation = —.